Company Overview
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Why Investors Should Care
Trades at a P/E of 0.2, below the sector median of 25.5.
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -2.9%.
- 5-Year Trend Long-term compounding — profit CAGR -3.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -2.90% |
Compounded Profit Growth
| 5 Years: | -3.47% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -79.08% |
| 6 Months: | -38.08% |
| 3 Months: | -36.97% |
| 1 Month: | -6.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.04 · Neutral
P/E of 0.18 is below the sector median of 25.51 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -3.5% CAGR over 5 years.
- Trading 82.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PSTV Plus Therapeutics, Inc. | 3.87 | 0.18 | $26.64M | 0.00% | - | - | - | -3.47% |
| 2 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 3 | WAT Waters Corporation SPX | 400.00 | 50.96 | $39.27B | 0.00% | 20.92% | 5.21% | 4.60% | 2.80% |
| 4 | ZTS Zoetis Inc. SPX | 74.39 | 12.20 | $31.19B | 2.74% | 27.18% | 67.75% | 5.92% | 18.61% |
| 5 | ZBH Zimmer Biomet Holdings, Inc. SPX | 98.16 | 25.43 | $18.99B | 1.02% | 6.61% | 6.07% | 4.50% | -0.54% |
| 6 | BTSG BrightSpring Health Services, Inc. R2K | 59.71 | 77.55 | $11.72B | 0.00% | 6.47% | 9.23% | 18.69% | - |
| 7 | NUVL Nuvalent, Inc. R2K | 123.96 | -20.46 | $9.12B | 0.00% | -31.35% | -41.19% | - | - |
| 8 | IBRX ImmunityBio, Inc. R2K | 7.17 | -8.44 | $7.51B | 0.00% | -58.17% | 70.21% | 54.76% | - |
| 9 | BLTE Belite Bio, Inc | 158.50 | -62.16 | $6.35B | 0.00% | -10.07% | -18.93% | - | -171.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 3.54M | 1.54M | 4.48M | 5.74M | 7.12M |
| Operating Income | - | -3.54M | -1.54M | -4.48M | -5.74M | -7.12M |
| EBITDA | - | -16.71M | 5.27M | -4.34M | -2.56M | -6.83M |
| Interest Expense | - | 548.00K | 0 | 0 | 3.06M | 17.00K |
| Pretax Income | - | -17.40M | 5.15M | -4.42M | -5.71M | -6.95M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -17.40M | 5.15M | -4.42M | -5.71M | -6.95M |
| Diluted EPS | - | -29.75 | 0.25 | -1.00 | - | -1.05 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 19.71M | 13.32M | 14.70M | 15.30M |
| Operating Income | - | -19.71M | -13.32M | -14.70M | -15.30M |
| EBITDA | - | -18.95M | -12.29M | -8.38M | -18.33M |
| Interest Expense | - | 711.00K | 395.00K | 3.72M | 3.61M |
| Pretax Income | - | -20.27M | -13.32M | -12.98M | -22.39M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -20.27M | -13.32M | -12.98M | -22.39M |
| Diluted EPS | - | -288.75 | -106.00 | -58.50 | -7.25 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 23.87M | 11.39M | 6.63M | 16.32M |
| Current Assets | - | 21.82M | 9.83M | 5.26M | 15.17M |
| Cash & Equivalents | - | 18.12M | 8.55M | 76.00K | 4.26M |
| Inventory | - | - | - | - | - |
| Receivables | 7.00K | - | 0 | 571.00K | 322.00K |
| Total Liabilities | - | 17.42M | 12.74M | 15.58M | 12.33M |
| Current Liabilities | - | 11.85M | 10.73M | 15.55M | 12.31M |
| Long Term Debt | 5.00M | 3.79M | - | - | - |
| Total Debt | - | 5.64M | 4.18M | 3.37M | 821.00K |
| Total Equity | - | 6.45M | -1.35M | -8.95M | 4.00M |
| Shares Outstanding | - | 89.60K | 180.91K | 246.19K | 5.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -12.97M | -12.85M | -10.55M | -20.77M |
| Investing Cash Flow | - | -759.00K | -160.00K | -4.11M | -854.00K |
| Financing Cash Flow | - | 13.45M | 3.44M | 6.19M | 30.31M |
| Capital Expenditure | - | -759.00K | -160.00K | -691.00K | -67.00K |
| Free Cash Flow | - | -13.73M | -13.01M | -11.24M | -20.84M |
| Net Change in Cash | - | -280.00K | -9.57M | -8.48M | 8.68M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -314.6% | 987.8% | 145.0% | -560.2% |
| ROCE % | - | -164.1% | -2,015.3% | 164.8% | -381.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 1.41% | 97.08K | $375.71K |
| 2 | Geode Capital Management, LLC | 1.17% | 80.65K | $312.12K |
| 3 | Blackrock Inc. | 1.03% | 71.06K | $274.98K |
| 4 | Vanguard Fiduciary Trust Co | 0.68% | 46.55K | $180.15K |
| 5 | Ashton Thomas Private Wealth, LLC | 0.50% | 34.31K | $132.76K |
| 6 | State Street Corporation | 0.27% | 18.76K | $72.58K |
| 7 | Northern Trust Corporation | 0.17% | 11.73K | $45.40K |
| 8 | Millennium Management Llc | 0.16% | 10.86K | $42.04K |
| 9 | Two Sigma Securities, LLC | 0.08% | 5.71K | $22.11K |
| 10 | Xtx Topco Ltd | 0.07% | 4.64K | $17.96K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PSTV
Cerenome Launches as an Integrated CNS Oncology Company
Formerly known as Plus Therapeutics, Cerenome integrates precision diagnostics, targeted therapeutics, and artificial intelligence to improve how CNS cancers are detected, treated, and understoodHOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Pl…
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
Posters will highlight research across the Company’s REYOBIQ™ clinical development program and CNSide® cerebrospinal fluid diagnostic platformHOUSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”),…
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a regional agreement with Medical Mutual e…
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells alongside tumor-derived D…
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal pat…
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company focused on central nervous system (“CNS”) cancers, today provides a comprehensive business update. Notably, the Company announces it is changing its com…
PSTV — Frequently Asked Questions
What is the current share price of Plus Therapeutics, Inc. (PSTV)?
As of 2026-08-05 17:25 PDT, Plus Therapeutics, Inc. (PSTV) trades at $3.87 on NasdaqCM. Its 52-week range is $2.92 to $22.25.
What is the market capitalisation of PSTV?
Plus Therapeutics, Inc. (PSTV) has a market capitalisation of $26.64M on NasdaqCM.
What is the P/E ratio of PSTV?
PSTV trades at a trailing price-to-earnings (P/E) ratio of 0.18. The industry average P/E is 25.51. Its price-to-book (P/B) ratio is 2.22.
Is PSTV a good stock to buy?
This page provides a data-driven analysis of Plus Therapeutics, Inc. (PSTV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.